| Literature DB >> 35445135 |
Massimo Origoni1, Francesco Cantatore1, Giorgio Candotti1, Massimo Candiani1.
Abstract
Objective: The objective of the present study was to investigate the potential prognostic role of neutrophil-lymphocyte ratio (NLR) in comparison with known parameters of prediction for the detection of recurrences of cervical intraepithelial neoplasia (CIN) after treatment.Entities:
Mesh:
Year: 2022 PMID: 35445135 PMCID: PMC9015869 DOI: 10.1155/2022/1149789
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1NLR receiver operating characteristic (ROC) curve analysis.
Figure 2Study design.
Demographics and clinical-pathological parameters of study cohort.
| Study cohort ( | ||
|---|---|---|
| Age (years) | ||
| Min. | 18 | |
| Max. | 73 | |
| Media | 38.4 (±9.5) | |
| Median (I.Q.R.) | 37.5 (31-44) | |
| Cone histology | CIN 1 | 39 (9.1%) |
| CIN 2 | 192 (44.9%) | |
| CIN 3 | 162 (37.9%) | |
| CA “in situ” | 33 (7.7%) | |
| G-CIN 2 | 1 (0.2%) | |
| G-CIN 3 | 1 (0.2%) | |
| HPV post-treatment | ||
| Positive | 115 (27%) | |
| Negative | 313 (73%) | |
| Margins | ||
| Positive | 65 (15.2%) | |
| Negative | 363 (84.8%) | |
| Recurrences | ||
| Yes | 86 | |
|
| ||
|
| ||
| No | 342 |
NLR subgroups and risk factors analysis.
| NLR <2 | NLR ≥2 |
| |
|---|---|---|---|
| Age (years) | 38.0 (±9.7) | 39.0 (±9.4) | 0.484 |
| WBC (mean) | 6412.5 (±1523.8) | 7801.1 (±1916.8) | <0.001 |
| Lymphocyte | 2371.1 (±569.2) | 1913.9 (±496.3) | 0.123 |
| Neutrophil | 3392.6 (±994.6) | 5187.2 (±1504.7) | <0.001 |
| Histology | |||
| CIN 1 | 27 (10.5%) | 12 (7.0%) | |
| CIN 2 | 114 (44.5%) | 78 (45.3%) | |
| CIN 3 | 96 (37.5%) | 66 (38.4%) | 0.597 |
| CA “in situ” | 17 (6.6%) | 16 (9.3%) | |
| G-CIN 2 | 1 (0.4%) | / | |
| G-CIN 3 | 1 (0.4%) | / | |
| Margins | |||
| Positive | 38 (14.9%) | 25 (15.3%) | 0.518 |
| Negative | 215 (85.1%) | 138 (84.7%) | |
| HPV post-treatment | |||
| Positive | 76 (30%) | 39 (24%) | 0.166 |
| Negative | 180 (70%) | 133 (76%) | |
| Recurrences | 39/256 (15.2%) | 47/172 (27.3%) | 0.003 |
| CIN2+ recurrences | 17/256 (6.5%) | 18/172 (10.5%) | 0.05 |
| Recurrences | 27/218 (12.4%) | 34/146 (23%) | 0.008 |
Univariate and multivariate recurrence risk assessment.
| Rec + | Rec - | Univariate | Multivariate | |
|---|---|---|---|---|
| Age (years) | ||||
| ≤30 | 23 | 73 |
|
|
| 31-44 | 39 | 189 | ||
| ≥45 | 24 | 80 | ||
| NLR | ||||
| <2 | 39 | 217 |
|
|
| ≥2 | 47 | 125 |
|
|
| Hr-HPV (post-LEEP) | ||||
| Negative | 50 | 263 |
|
|
| Positive | 36 | 79 |
|
|
| Margins | ||||
| Positive | 25 | 40 |
|
|
| Negative | 61 | 302 |
|
|
| Smoking | ||||
| Yes | 37 | 139 |
|
|
| No | 49 | 203 | ||
| E/P | ||||
| Yes | 15 | 97 |
|
|
| No | 71 | 245 |
Rec = recurrence; N.S. = not significant.